[1] 赵玉杰, 茅奇峰, 李情操, 等. 导管相关性血流感染的病原菌检测及影响因素分析[J]. 中国卫生检验杂志, 2017, 27(4): 470.
[2] NARDUCCI F, JEANLAURENT M, BOULANGER L, et al. Totally implantable venous access port systems and risk factors for complications: a one-year prospective study in a cancer centre[J]. Eur J Surg Oncol, 2011, 37(10): 913. doi: 10.1016/j.ejso.2011.06.016
[3] 文砚, 芳万笑. 植入静脉输液港与PICC在乳腺癌化疗患者中的效果分析[J]. 护理实践与研究, 2018, 15(4): 132.
[4] 中华医学会外科学分会血管外科分组. 深静脉血栓形成的诊断和治疗指南[J]. 中华普通外科学杂志, 2017, 32(9): 807.
[5] 邢磊, 孔令泉, 厉红元, 等. 乳腺癌患者携带PICC化疗并发PICC相关性上肢深静脉血栓形成的诊治探讨[J]. 中国肿瘤临床, 2011, 38(1): 1223.
[6] 毛美芬, 徐文亚, 高雪娟, 等. 乳腺癌化疗患者输液港相关血栓形成的影响因素[J]. 护理学杂志, 2019, 34(11): 33.
[7] KANG J, CHEN W, SUN W, et al. Peripherally inserted central catheter-related complications in cancer patients: approspective study of over 50, 000 catheter days[J]. J Vasc Access, 2017, 18(2): 153.
[8] ALMASI-SPERLING V, HIEBER S, LERMANN J, et al. Femoral placement of totally implantable venous access ports in patients with bilateral breast cancer[J]. Geburtshife Frauenheilkd, 2016, 76(1): 53.
[9] CHANG YF, LO AC, TSAI CH, et al. Higher complication risk of totally implantable venous access port systems in patients with advanced cancer—a single institution retrospective analysis[J]. Palliat Med, 2013, 27(2): 185.
[10] LI Z. SC17.02 lung cancer in china: challenges and perspectives[J]. J Thora Oncol, 2017, 12(1): S113.
[11] 崔向丽, 万子睿, 侯珂露, 等. 增加肿瘤患者血栓风险的药物概述[J]. 中国药物警戒, 2017, 14(7): 430.
[12] LEUNG TK, LEE CM, TAI CJ, et al. Aretrospective study on the long-term placement of peripherally inserted central catheters and the importance of nursing care and education[J]. Cancer Nurs, 2011, 34(1): 25.
[13] 闻曲. PICC临床应用中的安全隐患及管理现状[J]. 护理学杂志, 2013, 28(14): 6.
[14] 何晓容, 沈英. 社区PICC专业护士规范化培训的效果[J]. 护理学杂志, 2018, 33(13): 52.
[15] 施如春, 智晓旭, 孟爱凤, 等. 居家肿瘤患者不同中心静脉导管堵管危险因素分析[J]. 护理学杂志, 2019, 34(11): 36.